Accelerated Abeta aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. 2004

Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
Department of Alzheimer's Disease Research, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, 36-3 Gengo, Morioka, Obu 474-8522, Japan.

Aging and apolipoprotein E4 (apoE4) expression are strong risk factors for the development of Alzheimer's disease (AD); however, their pathological roles remain to be clarified. In the process of AD development, the conversion of the nontoxic amyloid beta-protein (Abeta) monomer to its toxic aggregates is a fundamental process. We previously hypothesized that Abeta aggregation is accelerated through the generation of GM1 ganglioside (GM1)-bound Abeta which acts as a seed for Abeta fibril formation. Here we report that GM1 level in detergent-resistant membrane microdomains (DRMs) of synaptosomes increased with age and that this increase was significantly pronounced in the apoE4- than the apoE3-knock-in mouse brain. Furthermore, we show that Abeta aggregation is markedly accelerated in the presence of the synaptosomes of the aged apoE4-knock-in mouse brain. These observations suggest that aging and apoE4 expression cooperatively accelerate Abeta aggregation in the brain through an increase in the level of GM1 in neuronal membranes.

UI MeSH Term Description Entries
D008297 Male Males
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D005677 G(M1) Ganglioside A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis. GM1 Ganglioside,Monosialosyl Tetraglycosyl Ceramide,GM1a Monosialoganglioside,Ceramide, Monosialosyl Tetraglycosyl,Ganglioside, GM1,Monosialoganglioside, GM1a,Tetraglycosyl Ceramide, Monosialosyl
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D013574 Synaptosomes Pinched-off nerve endings and their contents of vesicles and cytoplasm together with the attached subsynaptic area of the membrane of the post-synaptic cell. They are largely artificial structures produced by fractionation after selective centrifugation of nervous tissue homogenates. Synaptosome
D016229 Amyloid beta-Peptides Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. Alzheimer beta-Protein,Amyloid Protein A4,Amyloid beta-Peptide,Amyloid beta-Protein,beta Amyloid,beta-Amyloid Protein,Alzheimer's ABP,Alzheimer's Amyloid Fibril Protein,Amyloid AD-AP,Amyloid Fibril Protein, Alzheimer's,Amyloid beta-Proteins,ABP, Alzheimer's,AD-AP, Amyloid,Alzheimer ABP,Alzheimer beta Protein,Alzheimers ABP,Amyloid AD AP,Amyloid beta Peptide,Amyloid beta Peptides,Amyloid beta Protein,Amyloid beta Proteins,Amyloid, beta,Protein A4, Amyloid,Protein, beta-Amyloid,beta Amyloid Protein,beta-Peptide, Amyloid,beta-Peptides, Amyloid,beta-Protein, Alzheimer,beta-Protein, Amyloid,beta-Proteins, Amyloid
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
August 2002, Neurochemical research,
Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
May 2007, Biochimica et biophysica acta,
Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
May 1997, Biochemical Society transactions,
Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
August 1993, Molecular and chemical neuropathology,
Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
April 1995, Experimental neurology,
Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
December 2003, Biopolymers,
Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
January 2007, Zhurnal evoliutsionnoi biokhimii i fiziologii,
Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
January 1990, Developmental neuroscience,
Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
February 1990, Brain research,
Naoki Yamamoto, and Urule Igbabvoa, and Yukiko Shimada, and Yoshiko Ohno-Iwashita, and Mariko Kobayashi, and W Gibson Wood, and Shinobu C Fujita, and Katsuhiko Yanagisawa
September 2020, Membranes,
Copied contents to your clipboard!